IBDEI1BL ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21340,1,4,0)
 ;;=4^I50.810
 ;;^UTILITY(U,$J,358.3,21340,2)
 ;;=^5151384
 ;;^UTILITY(U,$J,358.3,21341,0)
 ;;=I50.811^^70^913^63
 ;;^UTILITY(U,$J,358.3,21341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21341,1,3,0)
 ;;=3^Heart Failure,Right,Acute
 ;;^UTILITY(U,$J,358.3,21341,1,4,0)
 ;;=4^I50.811
 ;;^UTILITY(U,$J,358.3,21341,2)
 ;;=^5151385
 ;;^UTILITY(U,$J,358.3,21342,0)
 ;;=I50.812^^70^913^65
 ;;^UTILITY(U,$J,358.3,21342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21342,1,3,0)
 ;;=3^Heart Failure,Right,Chronic
 ;;^UTILITY(U,$J,358.3,21342,1,4,0)
 ;;=4^I50.812
 ;;^UTILITY(U,$J,358.3,21342,2)
 ;;=^5151386
 ;;^UTILITY(U,$J,358.3,21343,0)
 ;;=I50.813^^70^913^64
 ;;^UTILITY(U,$J,358.3,21343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21343,1,3,0)
 ;;=3^Heart Failure,Right,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,21343,1,4,0)
 ;;=4^I50.813
 ;;^UTILITY(U,$J,358.3,21343,2)
 ;;=^5151387
 ;;^UTILITY(U,$J,358.3,21344,0)
 ;;=I21.A1^^70^913^72
 ;;^UTILITY(U,$J,358.3,21344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21344,1,3,0)
 ;;=3^Myocardial Infarction,Type 2
 ;;^UTILITY(U,$J,358.3,21344,1,4,0)
 ;;=4^I21.A1
 ;;^UTILITY(U,$J,358.3,21344,2)
 ;;=^5151374
 ;;^UTILITY(U,$J,358.3,21345,0)
 ;;=I48.11^^70^913^46
 ;;^UTILITY(U,$J,358.3,21345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21345,1,3,0)
 ;;=3^Atrial Fibrillation,Longstanding Persistent
 ;;^UTILITY(U,$J,358.3,21345,1,4,0)
 ;;=4^I48.11
 ;;^UTILITY(U,$J,358.3,21345,2)
 ;;=^5158046
 ;;^UTILITY(U,$J,358.3,21346,0)
 ;;=I48.19^^70^913^44
 ;;^UTILITY(U,$J,358.3,21346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21346,1,3,0)
 ;;=3^Atrial Fibrillation,Chr Persistent
 ;;^UTILITY(U,$J,358.3,21346,1,4,0)
 ;;=4^I48.19
 ;;^UTILITY(U,$J,358.3,21346,2)
 ;;=^5158047
 ;;^UTILITY(U,$J,358.3,21347,0)
 ;;=I48.20^^70^913^45
 ;;^UTILITY(U,$J,358.3,21347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21347,1,3,0)
 ;;=3^Atrial Fibrillation,Chr Unspec
 ;;^UTILITY(U,$J,358.3,21347,1,4,0)
 ;;=4^I48.20
 ;;^UTILITY(U,$J,358.3,21347,2)
 ;;=^5158048
 ;;^UTILITY(U,$J,358.3,21348,0)
 ;;=I48.21^^70^913^48
 ;;^UTILITY(U,$J,358.3,21348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21348,1,3,0)
 ;;=3^Atrial Fibrillation,Permanent
 ;;^UTILITY(U,$J,358.3,21348,1,4,0)
 ;;=4^I48.21
 ;;^UTILITY(U,$J,358.3,21348,2)
 ;;=^304710
 ;;^UTILITY(U,$J,358.3,21349,0)
 ;;=Z79.82^^70^913^71
 ;;^UTILITY(U,$J,358.3,21349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21349,1,3,0)
 ;;=3^Long Term (Current) Use of Aspirin
 ;;^UTILITY(U,$J,358.3,21349,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,21349,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,21350,0)
 ;;=Z79.01^^70^913^69
 ;;^UTILITY(U,$J,358.3,21350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21350,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,21350,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,21350,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,21351,0)
 ;;=Z79.02^^70^913^70
 ;;^UTILITY(U,$J,358.3,21351,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21351,1,3,0)
 ;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,21351,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,21351,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,21352,0)
 ;;=E87.8^^70^914^12
 ;;^UTILITY(U,$J,358.3,21352,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21352,1,3,0)
 ;;=3^Electrolyte/Fluid Balance Disorders NEC
 ;;^UTILITY(U,$J,358.3,21352,1,4,0)
 ;;=4^E87.8
